Loading…
Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
Purpose The aim of the study was to compare sequential 177 Lu-DOTA-TATE planar scans ( 177 Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic 68 Ga-DOTA-TATE positron em...
Saved in:
| Published in: | European journal of nuclear medicine and molecular imaging 2012-03, Vol.39 (3), p.501-511 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43 |
| container_end_page | 511 |
| container_issue | 3 |
| container_start_page | 501 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 39 |
| creator | Sainz-Esteban, Aurora Prasad, Vikas Schuchardt, Christiane Zachert, Carolin Carril, José Manuel Baum, Richard P. |
| description | Purpose
The aim of the study was to compare sequential
177
Lu-DOTA-TATE planar scans (
177
Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic
68
Ga-DOTA-TATE positron emission tomography (PET)/CT (
68
Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods.
Methods
A total of 44 patients (59 ± 11 years old) with biopsy-proven NET underwent
68
Ga-DOTA-TATE and
177
Lu-DOTA-TATE imaging within 7.9 ± 7.5 days between the two examinations.
177
Lu-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on
177
Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on
68
Ga-DOTA-TATE studies obtained before PRRT.
Results
A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were
68
Ga-DOTA-TATE positive and
177
Lu-DOTA-TATE negative, whereas 9 were
68
Ga-DOTA-TATE negative and
177
Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for
177
Lu-DOTA-TATE as compared to
68
Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h)
177
Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (
n
= 77; mean size 3.8 cm) were significantly larger than discordant lesions (
n
= 38; mean size 1.6 cm) (
p
|
| doi_str_mv | 10.1007/s00259-011-2003-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_921142213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>921142213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhlcIREvhAbgg3ziZ2t4Q28cohIIUqRyWs-WMZ1NXu_Zir0XCC_JaOEqoOCFbmpH9zS_N_zfNW84-cMbkbWZMfNSUcU4FYy09PGuu-ZJrKpnSz596ya6aVzk_MsaVUPplcyUEVy1n6rr5vY7jZJPPMZDYk4w_CobZ24FMgw02ES7lttBP992KdqtuQ1zMfsQ5HUkGGzL56ecHslR39h_m26a7XXfEj3aPmfhAJjv7Knuh67jN9fpf6EjAkiIGFyH5gGQuYywpkxIcpn30YU8mnGbvkCSE2sVEknU-hgLD6XV-wGSn4-vmRW-HjG8u9ab5_nnTrb_Q7f3d1_VqS4ErdaDAXD0adkxq0YPqF64WzV0rUMKyF_2ylWwHGpRohZJCtdaCAgC5g94t2pvm_Vl3SrFalWcz-gw4VLMwlmy04HxR7W0ryc8kpJhzwt5MqTqSjoYzc4rPnOMzNT5zis8c6sy7i3rZjeieJv7mVQFxBnL9CntM5rHaFerG_1H9A66eqiI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>921142213</pqid></control><display><type>article</type><title>Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy</title><source>Springer Nature</source><creator>Sainz-Esteban, Aurora ; Prasad, Vikas ; Schuchardt, Christiane ; Zachert, Carolin ; Carril, José Manuel ; Baum, Richard P.</creator><creatorcontrib>Sainz-Esteban, Aurora ; Prasad, Vikas ; Schuchardt, Christiane ; Zachert, Carolin ; Carril, José Manuel ; Baum, Richard P.</creatorcontrib><description>Purpose
The aim of the study was to compare sequential
177
Lu-DOTA-TATE planar scans (
177
Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic
68
Ga-DOTA-TATE positron emission tomography (PET)/CT (
68
Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods.
Methods
A total of 44 patients (59 ± 11 years old) with biopsy-proven NET underwent
68
Ga-DOTA-TATE and
177
Lu-DOTA-TATE imaging within 7.9 ± 7.5 days between the two examinations.
177
Lu-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on
177
Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on
68
Ga-DOTA-TATE studies obtained before PRRT.
Results
A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were
68
Ga-DOTA-TATE positive and
177
Lu-DOTA-TATE negative, whereas 9 were
68
Ga-DOTA-TATE negative and
177
Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for
177
Lu-DOTA-TATE as compared to
68
Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h)
177
Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (
n
= 77; mean size 3.8 cm) were significantly larger than discordant lesions (
n
= 38; mean size 1.6 cm) (
p
< 0.05). No such significance was found for differences in maximum standardized uptake value (SUV
max
). However, concordant liver lesions with a score from 1 to 3 in the 72-h
177
Lu-DOTA-TATE scan had a lower SUV
max
(
n
= 23; mean 10.9) than those metastases with a score of 4 (
n
= 97; mean SUV
max
18) (
p
< 0.05).
Conclusion
Although
177
Lu-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for the detection of metastases, they failed to pick up 9% of lesions seen on the
68
Ga-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-011-2003-x</identifier><identifier>PMID: 22183108</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Cardiology ; Female ; Humans ; Imaging ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multimodal Imaging - methods ; Neoplasm Metastasis ; Neuroendocrine Tumors - diagnostic imaging ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - radiotherapy ; Nuclear Medicine ; Octreotide - analogs & derivatives ; Oncology ; Organometallic Compounds ; Original Article ; Orthopedics ; Positron-Emission Tomography ; Radiology ; Radiometry ; Receptors, Peptide - therapeutic use ; Retrospective Studies ; Time Factors ; Tomography, X-Ray Computed ; Young Adult</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2012-03, Vol.39 (3), p.501-511</ispartof><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43</citedby><cites>FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22183108$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sainz-Esteban, Aurora</creatorcontrib><creatorcontrib>Prasad, Vikas</creatorcontrib><creatorcontrib>Schuchardt, Christiane</creatorcontrib><creatorcontrib>Zachert, Carolin</creatorcontrib><creatorcontrib>Carril, José Manuel</creatorcontrib><creatorcontrib>Baum, Richard P.</creatorcontrib><title>Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
The aim of the study was to compare sequential
177
Lu-DOTA-TATE planar scans (
177
Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic
68
Ga-DOTA-TATE positron emission tomography (PET)/CT (
68
Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods.
Methods
A total of 44 patients (59 ± 11 years old) with biopsy-proven NET underwent
68
Ga-DOTA-TATE and
177
Lu-DOTA-TATE imaging within 7.9 ± 7.5 days between the two examinations.
177
Lu-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on
177
Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on
68
Ga-DOTA-TATE studies obtained before PRRT.
Results
A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were
68
Ga-DOTA-TATE positive and
177
Lu-DOTA-TATE negative, whereas 9 were
68
Ga-DOTA-TATE negative and
177
Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for
177
Lu-DOTA-TATE as compared to
68
Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h)
177
Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (
n
= 77; mean size 3.8 cm) were significantly larger than discordant lesions (
n
= 38; mean size 1.6 cm) (
p
< 0.05). No such significance was found for differences in maximum standardized uptake value (SUV
max
). However, concordant liver lesions with a score from 1 to 3 in the 72-h
177
Lu-DOTA-TATE scan had a lower SUV
max
(
n
= 23; mean 10.9) than those metastases with a score of 4 (
n
= 97; mean SUV
max
18) (
p
< 0.05).
Conclusion
Although
177
Lu-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for the detection of metastases, they failed to pick up 9% of lesions seen on the
68
Ga-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiology</subject><subject>Female</subject><subject>Humans</subject><subject>Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multimodal Imaging - methods</subject><subject>Neoplasm Metastasis</subject><subject>Neuroendocrine Tumors - diagnostic imaging</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Neuroendocrine Tumors - radiotherapy</subject><subject>Nuclear Medicine</subject><subject>Octreotide - analogs & derivatives</subject><subject>Oncology</subject><subject>Organometallic Compounds</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Radiometry</subject><subject>Receptors, Peptide - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Tomography, X-Ray Computed</subject><subject>Young Adult</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kcFuEzEQhlcIREvhAbgg3ziZ2t4Q28cohIIUqRyWs-WMZ1NXu_Zir0XCC_JaOEqoOCFbmpH9zS_N_zfNW84-cMbkbWZMfNSUcU4FYy09PGuu-ZJrKpnSz596ya6aVzk_MsaVUPplcyUEVy1n6rr5vY7jZJPPMZDYk4w_CobZ24FMgw02ES7lttBP992KdqtuQ1zMfsQ5HUkGGzL56ecHslR39h_m26a7XXfEj3aPmfhAJjv7Knuh67jN9fpf6EjAkiIGFyH5gGQuYywpkxIcpn30YU8mnGbvkCSE2sVEknU-hgLD6XV-wGSn4-vmRW-HjG8u9ab5_nnTrb_Q7f3d1_VqS4ErdaDAXD0adkxq0YPqF64WzV0rUMKyF_2ylWwHGpRohZJCtdaCAgC5g94t2pvm_Vl3SrFalWcz-gw4VLMwlmy04HxR7W0ryc8kpJhzwt5MqTqSjoYzc4rPnOMzNT5zis8c6sy7i3rZjeieJv7mVQFxBnL9CntM5rHaFerG_1H9A66eqiI</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Sainz-Esteban, Aurora</creator><creator>Prasad, Vikas</creator><creator>Schuchardt, Christiane</creator><creator>Zachert, Carolin</creator><creator>Carril, José Manuel</creator><creator>Baum, Richard P.</creator><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy</title><author>Sainz-Esteban, Aurora ; Prasad, Vikas ; Schuchardt, Christiane ; Zachert, Carolin ; Carril, José Manuel ; Baum, Richard P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiology</topic><topic>Female</topic><topic>Humans</topic><topic>Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multimodal Imaging - methods</topic><topic>Neoplasm Metastasis</topic><topic>Neuroendocrine Tumors - diagnostic imaging</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Neuroendocrine Tumors - radiotherapy</topic><topic>Nuclear Medicine</topic><topic>Octreotide - analogs & derivatives</topic><topic>Oncology</topic><topic>Organometallic Compounds</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Radiometry</topic><topic>Receptors, Peptide - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Tomography, X-Ray Computed</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sainz-Esteban, Aurora</creatorcontrib><creatorcontrib>Prasad, Vikas</creatorcontrib><creatorcontrib>Schuchardt, Christiane</creatorcontrib><creatorcontrib>Zachert, Carolin</creatorcontrib><creatorcontrib>Carril, José Manuel</creatorcontrib><creatorcontrib>Baum, Richard P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sainz-Esteban, Aurora</au><au>Prasad, Vikas</au><au>Schuchardt, Christiane</au><au>Zachert, Carolin</au><au>Carril, José Manuel</au><au>Baum, Richard P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2012-03</date><risdate>2012</risdate><volume>39</volume><issue>3</issue><spage>501</spage><epage>511</epage><pages>501-511</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
The aim of the study was to compare sequential
177
Lu-DOTA-TATE planar scans (
177
Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic
68
Ga-DOTA-TATE positron emission tomography (PET)/CT (
68
Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods.
Methods
A total of 44 patients (59 ± 11 years old) with biopsy-proven NET underwent
68
Ga-DOTA-TATE and
177
Lu-DOTA-TATE imaging within 7.9 ± 7.5 days between the two examinations.
177
Lu-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on
177
Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on
68
Ga-DOTA-TATE studies obtained before PRRT.
Results
A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were
68
Ga-DOTA-TATE positive and
177
Lu-DOTA-TATE negative, whereas 9 were
68
Ga-DOTA-TATE negative and
177
Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for
177
Lu-DOTA-TATE as compared to
68
Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h)
177
Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (
n
= 77; mean size 3.8 cm) were significantly larger than discordant lesions (
n
= 38; mean size 1.6 cm) (
p
< 0.05). No such significance was found for differences in maximum standardized uptake value (SUV
max
). However, concordant liver lesions with a score from 1 to 3 in the 72-h
177
Lu-DOTA-TATE scan had a lower SUV
max
(
n
= 23; mean 10.9) than those metastases with a score of 4 (
n
= 97; mean SUV
max
18) (
p
< 0.05).
Conclusion
Although
177
Lu-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for the detection of metastases, they failed to pick up 9% of lesions seen on the
68
Ga-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22183108</pmid><doi>10.1007/s00259-011-2003-x</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2012-03, Vol.39 (3), p.501-511 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_921142213 |
| source | Springer Nature |
| subjects | Adult Aged Aged, 80 and over Cardiology Female Humans Imaging Male Medicine Medicine & Public Health Middle Aged Multimodal Imaging - methods Neoplasm Metastasis Neuroendocrine Tumors - diagnostic imaging Neuroendocrine Tumors - pathology Neuroendocrine Tumors - radiotherapy Nuclear Medicine Octreotide - analogs & derivatives Oncology Organometallic Compounds Original Article Orthopedics Positron-Emission Tomography Radiology Radiometry Receptors, Peptide - therapeutic use Retrospective Studies Time Factors Tomography, X-Ray Computed Young Adult |
| title | Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T09%3A01%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20sequential%20planar%20177Lu-DOTA-TATE%20dosimetry%20scans%20with%2068Ga-DOTA-TATE%20PET/CT%20images%20in%20patients%20with%20metastasized%20neuroendocrine%20tumours%20undergoing%20peptide%20receptor%20radionuclide%20therapy&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Sainz-Esteban,%20Aurora&rft.date=2012-03&rft.volume=39&rft.issue=3&rft.spage=501&rft.epage=511&rft.pages=501-511&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-011-2003-x&rft_dat=%3Cproquest_cross%3E921142213%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c188x-c0d0d09cb0792fc8f4d2fc91d32e7c6f2f6370bc9c823287283aac8ccc7bcfd43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=921142213&rft_id=info:pmid/22183108&rfr_iscdi=true |